The US obesity market is set to grow from $533m to $1.2bn in the next 10 years, according to Datamonitor Healthcare’s obesity forecast. However, there is room for more dramatic growth long term should more efficacious therapeutics come to market. Fewer than than 1% of treatable patients currently receive a pharmacological intervention for obesity. The market could be worth $11.2bn by 2026 if the proportion of obese patients receiving drug therapy increased to 5%, or $22.4bn if it was 10% (see Figure 1).
The predicted boost in the obesity drug market will be mainly contributed by Novo Nordisk AS' liraglutide(Victoza/Saxenda), for which...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
